The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

Novartis has claimed accelerated approval from the FDA for a second ... are at risk of rapid disease progression, making it the first complement inhibitor for the rare kidney disease.

Novartis NVS announced that the FDA has approved breast ... with node-negative (N0) disease. Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the ...

1 Ribociclib is manufactured by Novartis for ... 3 “The FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, is a pivotal moment in improving our ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...

The FDA granted approval to Lilly’s Ebglyss for treating moderate-to-severe atopic dermatitis in adults and children aged 12 and above whose disease ... approval to Novartis’ drug Kisqali ...

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...

17, 2024 /PRNewswire/ -- Novartis today announced that the US Food and Drug ... "The FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, is a pivotal ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...